يعرض 1 - 20 نتائج من 30 نتيجة بحث عن '"ишемическая нейропатия"', وقت الاستعلام: 0.43s تنقيح النتائج
  1. 1
    Academic Journal

    المصدر: Ophthalmology in Russia; Том 21, № 1 (2024); 178-185 ; Офтальмология; Том 21, № 1 (2024); 178-185 ; 2500-0845 ; 1816-5095 ; 10.18008/1816-5095-2024-1

    وصف الملف: application/pdf

    Relation: https://www.ophthalmojournal.com/opht/article/view/2309/1203; Бадимова АВ. Особенности эпидемиологии заболеваемости и инвалидности в связи с болезнями органов зрения в России и за рубежом. Наука молодых (Eruditio Juvenium). 2020;8(2):261–268. doi:10.23888/HMJ202082261-268.; GBD 2019 Blindness and Vision Impairment Collaborators, Trends in prevalence of blindness and distance and near vision impairment over 30 years: an analysis for the Global Burden of Disease Study, Lancet Glob Health. 2021;9:e130–143 Published Online, December 1, 2020. https://www.thelancet.com/journals/langlo/article/PIIS2214-109X(20)30425-3/fulltext. doi:10.1016/S2214-109X(20)30425-3.; Нероев ВВ. Организация офтальмологической помощи населению Российской Федерации. Вестник офтальмологии. 2014;130(6):8–12.; Papaliodis GN. Ophthalmologic manifestations of systemic vasculitis. Current Opinion in Ophthalmology. 2017;28(6):613–616. doi:10.1097/ICU.0000000000000422.; Yates M, MacGregor AJ, Robson J, Craven A, Merkel PA, Luqmani RA, Watts RA. The association of vascular risk factors with visual loss in giant cell arteritis. Rheumatology. 2017;56(4):524–528. doi:10.1093/rheumatology/kew397; Грачев ЮВ. Неврологические проявления гигантоклеточного артериита. Журнал неврологии и психиатрии им. С.С. Корсакова. 2016;116(1):82–89. doi:10.17116/jnevro20161161182-89.; Mahr A, Hachulla E, de Boysson H, Guerroui N, Héron E, Vinzio S, Broner J, Lapébie FX, Michaud M, Sailler L, Zenone T, Djerad M, Jouvray M, Shipley E, Tieulie N, Armengol G, Bouldoires B, Viallard JF, Idier I, Paccalin M, Devauchelle-Pensec V. Presentation and Real-World Management of Giant Cell Arteritis (Artemis Study). Front Med (Lausanne). 2021:11:732934. doi:10.3389/fmed.2021.732934.; Головач ИЮ, Егудина ЕД, Бевзенко ТБ. Поражения глаз при системных васкулитах. Кардиология, ревматология, кардиохирургия. 2018;58(3):58–61.; https://www.ophthalmojournal.com/opht/article/view/2309

  2. 2
    Academic Journal

    المصدر: Ophthalmology in Russia; Том 16, № 1 (2019); 109-114 ; Офтальмология; Том 16, № 1 (2019); 109-114 ; 2500-0845 ; 1816-5095 ; 10.18008/1816-5095-2019-1

    وصف الملف: application/pdf

    Relation: https://www.ophthalmojournal.com/opht/article/view/867/568; Dasgupta B., Borg F.A., Hassan N., et al. BSR and BHPR guidelines for the management of giant cell arteritis. Rheumatology (Oxford). 2010;49(8):1594–1597. DOI:10.1093/rheumatology/keq039a; Nesher G. The diagnosis and classification of giant cell arteritis. J Autoimmun. 2014 Feb-Mar;48–49:73–75. DOI:10.1016/j.jaut.2014.01.017; Alvarez-Lafuente R., Fernández-Gutiérrez B., Jover J.A., et al. Human parvovirus B19, varicella zoster virus, and human herpes virus 6 in temporal artery biopsy specimens of patient with giant cell arteritis: analysis with quantitative real time polymerase chain reaction. Ann Rheum Dis. 2005 May;64(5):780–782.; Elling P., Olsson A.T., Elling H. Synchronous variations of the incidence of temporal arteritis and polymyalgia rheumatica in different regions of Denmark; associations with epidemics of Mycoplasma pneumoniae infection. J. Reumatol. 1996;23(1):112–119.; Haugeberg G., Bie R., Nordbø S.A. Temporal arteritis associated with Chlamydia pneumoniae DNA detected in an artery specimen. J Rheumatol. 2001:28(7):1738–1739.; Gilden D., Nagel M.A. Varicella zoster virus and giant cell arteritis. Curr Opin Infect Dis. 2016;29(3):275–279. DOI:10.1097/QCO.0000000000000258; Frohman L., Wong A.B., Matheos K., Leon-Alvarado L.G., Danesh-Meyer H.V. New developments in giant cell arteritis. Surv Ophthalmol. 2016;61(4):400–421. DOI:10.1016/j.survophthal.2016.01.001; Bhatt A.S., Manzo V.E., Pedamallu C.S., et al. In search of candidate pathogen for giant cell arteritis: sequencing — based characterization of the giant cell arteritis microbiome. Arthritis Rheumatol. 2014;66(7):1939–1944. DOI:10.1002/art.38631; Hayreh S.S., Zimmerman B. Management of giant cell arteritis. Our 27 — year clinical study: new light on old controversies. Ophthalmologica. 2003;217(4):239–259.; Weyand C.M., Goronzy J.J. Giant — cell arteritis and polymyalgia rheumatica. N Engl J Med. 2014 Oct 23;371(17):1653. DOI:10.1056/NEJMc1409206; Gonzalez-Gay M.A., Blanco R., Rodriguez-Valverde V., et al. Permanent visual loss and cerebrovascular accidents in giant cell arteritis: predictors and response to treatment. Arthr Rheum. 1998;41(8):1497–1504.; Hayreh S.S., Podhajsky P.A., Zimmerman B. Occult giant cell arteritis: ocular manifestation. Am J Ophthalmol. 1998;125(4):521–526.; Muratore F., Pipitone N., Salvarani C. Standard and biological treatment in large vessel vasculitis: guidelines and current approaches. Expert Rev Clin Immunol. 2017 Apr;13(4):345–360. DOI:10.1080/1744666X.2017.1285699; González-Gay M.A., García-Porrua C., Llorca J., Gonzalez-Louzano C., Rodriguez-Ledo P. Biopsy-negative giant cell arteritis: clinical spectrum and predictive factors for positive temporal artery biopsy. Semin Arthritis Rheum 2001;30(4):249–256.; Breuer G.S., Nesher R., Nesher G. Negative temporal artery biopsies: eventual diagnoses and features of patients with biopsy-negative giant cell arteritis compared to patients without arteritis. Clin Exp Rheumatol. 2008;26(6):1103–1106.; Breuer G.S., Nesher R., Nesher G. Effect of biopsy length on the rate of positive temporal artery biopsies. Clin Exp Rheumatol. 2009;27(1 Suppl. 52):S10–S13.; https://www.ophthalmojournal.com/opht/article/view/867

  3. 3
    Academic Journal

    المصدر: Ophthalmology in Russia; Том 16, № 4 (2019); 487-493 ; Офтальмология; Том 16, № 4 (2019); 487-493 ; 2500-0845 ; 1816-5095 ; 10.18008/1816-5095-2019-4

    وصف الملف: application/pdf

    Relation: https://www.ophthalmojournal.com/opht/article/view/1082/651; Schockman S., Glueck C.J., Hutchins R.K., Patel J., Shah P., Wang P. Diagnostic ramifications of ocular vascular occlusion as a first thrombotic event associated with factor V Leiden and prothrombin gene heterozygosity. Clinical Ophthalmology. 2015;9:591–600. DOI:10.2147/OPTH.S80714; Nagy V., Takacs L., Steiber Z, Pfliegler G., Berta A. Thrombophilic screening in retinal artery occlusion patients. Clinical Ophthalmology. 2008;2(3):557–561.; Pianka P., Almog Y., Man O., Goldstein M., Sela B.A., Loewenstein A. Hyperhomocystinemia in patients with nonarteritic anterior ischemic optic neuropathy, central retinal artery occlusion, and central retinal vein occlusion. Ophthalmology. 2000;107(8):1588–1592. DOI:10.1016/S0161‑6420(00)00181‑0; Salomon O., Huna‑Baron R., Moisseiev J., Rosenberg N., Rubovitz A., Steinberg D.M., Davidson J., Sela B.A., Seligsohn U. Thrombophilia as a cause for central and branch retinal artery occlusion in patients without an apparent embolic source. Eye. 2001;15(4):511–514. DOI:10.1038/eye.2001.164; Murin S., Marelich G.P., Arroliga A.C., Matthay R.A. Hereditary Thrombophilia and Venous Thromboembolism. American Journal of Respiratory and Critical Care Medicine. 1998;158(5):1369–1373. DOI:10.1164/ajrccm.158.5.9712022; De Stefano V., Chiusolo P., Paciaroni K., Leone G. Epidemiology of factor V Leiden: clinical implications. Seminars in Thrombosis and Hemostasis. 1998;24(4):367–379. DOI:10.1055/s‑2007‑996025; Kujovich J.L. Factor V Leiden thrombophilia. Genetics IN Medicine. 2011;13:1–16. DOI:10.1097/GIM.0b013e3181faa0f2; Nagy V., Facsko A., Takacs L., Balazs E., Berta A., Balogh I., Edes I., Czuriga I., Pfliegler G. Activated protein C resistance in anterior ischaemic optic Neuropathy. Acta Ophthalmologica Scandinavica. 2004;82:140–143. DOI:10.1111/j.1600‑0420.2004.00226.x; Gottlieb J.L., Blice J.P., Mestichelli B., Konkle B.A., Benson W.E. Activated Protein C Resistance, Factor V Leiden, and Central Retinal Vein Occlusion in Young Adults. Archives of Ophthalmology. 1998;116(5):577–579. DOI:10.1001/archopht.116.5.577; Dhar‑Munshi S., Ayliffe W.H., Jayne D. Branch Retinal Arteriolar Occlusion Associated with Familial Factor V Leiden Polymorphism and Positive Rheumatoid Factor. Archives of Ophthalmology. 1999;117(7):978–979.; Rosendaal F.R., Siscovick D.S., Schwartz S.M., Beverly R.K., Psaty B.M., Longstreth W.T. Jr, Raghunathan T.E., Koepsell T.D., Reitsma P.H. Factor V Leiden (resistance to activated protein C) increases the risk of myocardial infarction in young women. Blood. 1997;89:2817–2821.; Mannucci P.M. Fine particulate: it matters. Journal of Thrombosis and Haemostasis. 2010;8:659–661. DOI:10.1111/j.1538‑7836.2010.03804.x; Margaglione M., D’Andrea G., Giuliani N., et al. Inherited prothrombotic conditions and premature ischemic stroke: sex difference in the association with factor V Leiden. Arteriosclerosis, Thrombosis, and Vascular Biology. 1999;19:1751–1756.; Backhouse O., Parapia L., Mahomed I., Lee D. Familial thrombophilia and retinal vein occlusion. Eye. 2000;14:13–17. DOI:10.1038/eye.2000.4; Talman T., Scharf J., Meyer E., Lanir N. Miller B., Brenner B. Retinal arterial occlusion in a child with factor V Leiden and thermolabile methylene tetrahydrofolate reductase mutations. American Journal of Ophthalmology. 1997;124(5):689–691.; Tayyanipour R., Pulido J.S., Postel E.A., Lipkowitz J.L., Pisciotta A., Braza E. Arterial vascular occlusion associated with factor V Leiden gene mutation. Retina. 1998;18:376–377.; Bessero A.C., Borruat F.X. Visual dysfunction and arterial occlusion: is there an association with factor V Leiden mutation? Four case reports. Journal Francais D’Opthalmologie. 2006;29:43–46.; Frye R.E. Transient Visual Loss Associated with the Factor V Leiden Mutation. North American Journal of Medicine and Science. 2017;10(2):61–64. DOI:10.7156/najms.2017.1002061; Cursiefen C., Schonherr U., Schwender S., Grossmann R. Recurrent optic nerve headinfarctions associated with combined factor V Leiden‑ and factor II:G20210A‑mutation. Acta Ophthalmologica Scandinavica. 1999;77:625–627.; Lorca‑Barchín J., Medrano‑Martínez V., Francés‑Pont I., Fernández‑Izquierdo S., Mallada‑Frechin J., Piqueras‑Rodríguez L. Non‑Arteritic Anterior Ischemic Optic Neuropathy and Factor V Leiden. Journal of Neurological Disorders. 2015;2(3):303.; Пизова Н.В., Степанова М.В. Тромбофилии, связанные с резистентностью к активированному протеину С: генетические полиморфизмы и инсульт. Неврологический журнал. 2012;6:4–11.; Kapiotis S., Quehenberger P., Jilma B., Handler S., Pabinger‑Fasching I., Mannhalter C., Speiser W. Improved characteristics of aPC‑resistance assay: Coatest aPC resistance by predilution of samples with factor V deficient plasma. American Journal of Clinical Pathology. 1996;106:588–593. DOI:10.1093/ajcp/106.5.588; Grody W.W., Griffin J.H., Taylor A.K., Korf B.R., Heit J.A. Factor V Leiden Working Group. American College of Medical Genetics consensus statement on factor V Leiden mutation testing. Genetics in Medicine. 2001;3:139–148. DOI:10.109700125817‑200103000‑00009; Press R.D., Bauer K.A., Kujovich J.L., Heit J.A. Clinical utility of factor V Leiden (R506Q) testing for the diagnosis and management of thromboembolic disorders. Archives of Pathology & Laboratory Medicine. 2002;126(11):1304–1318. DOI:10.1043/0003‑9985(2002)1262.0.CO;2; https://www.ophthalmojournal.com/opht/article/view/1082

  4. 4
    Academic Journal

    Relation: Протективное действие карбамилированного дарбэпоэтина на модели ишемической нейропатии зрительного нерва у крыс / А.А. Пересыпкина [и др.] // Экспериментальная и клиническая фармакология. - 2018. - Т.81, №7.-С. 8-13. - Doi: DOI:10.30906/0869-2092-2018-81-7-8-13. - Библиогр.: с. 13.; http://dspace.bsu.edu.ru/handle/123456789/22686

  5. 5
    Academic Journal

    Relation: Коррекция экспериментальной ишемической нейропатии зрительного нерва агонистом имидазолиновых рецепторов типов I и II / А.А. Пересыпкина [и др.] // Экспериментальная и клиническая фармакология. - 2018. - Т.81, №4.-С. 12-17. - Doi:10.30906/0869-2092-2018-81-4-12-17. - Библиогр.: с. 16.; http://dspace.bsu.edu.ru/handle/123456789/22684

  6. 6
    Academic Journal
  7. 7
  8. 8
    Academic Journal

    المساهمون: SE "Dnipropetrovsk medical academy of Health Ministry of Ukraine" (DMA), «Dnepropetrovsk Municipal Clinical Hospital N 8»

    المصدر: ISSN: 2307-0404 ; Medical perspectives (Medicni Perspektivi) ; https://hal.archives-ouvertes.fr/hal-01525874 ; Medical perspectives (Medicni Perspektivi), SE "Dnipropetrovsk medical academy of Health Ministry of Ukraine", 2017, 22 (1), pp.50-54 ; http://medpers.dsma.dp.ua/issues/2017/N1/50-54.pdf.

  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
    Academic Journal

    Relation: Комиссарова, Ю. В. Эффективность лечения острой ишемической нейропатии по материалам Гомельского центра микрохирургии глаза / [Электронный ресурс] / Ю. В. Комиссарова // Проблемы и перспективы развития современной медицины : сб. науч. ст. V Респ. науч.-практ. конф. с междунар. участием студентов и молодых ученых, Гомель, 7-8 мая 2013 г. : в 4 т. / Гомел. гос. мед. ун-т; редкол. : А. Н. Лызиков [и др.]. – Гомель : ГомГМУ, 2013. – Т. 2. – С. 181–183. – 1 электрон. опт. диск (CD-ROM). Научный руководитель: к.м.н. Л. В. Дравица; http://elib.gsmu.by/handle/GomSMU/11489

  19. 19
  20. 20

    المصدر: INTERNATIONAL NEUROLOGICAL JOURNAL; № 2.64 (2014); 100-105
    МЕЖДУНАРОДНЫЙ НЕВРОЛОГИЧЕСКИЙ ЖУРНАЛ; № 2.64 (2014); 100-105
    МІЖНАРОДНИЙ НЕВРОЛОГІЧНИЙ ЖУРНАЛ; № 2.64 (2014); 100-105

    وصف الملف: application/pdf